SACUBITRIL
Cardiotoxicity
National Cheng-Kung University HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Cardiotoxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL Abramson Cancer Center at Penn Medicine | Phase 3 | BB |
SACUBITRIL VALSARTAN Silesian Centre for Heart Diseases | Phase 4 | B |
Captopril Children's Cancer Hospital Egypt 57357 | Phase 3 | B |
BISOPROLOL Azienda Ospedaliero-Universitaria Careggi | Phase 3 | B |
NEBIVOLOL Giulio Stefanini | Phase 3 | B |
View all 22 →
Same molecule, other indications
SACUBITRIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →